AstraZeneca Pharmaceuticals LP
NEWS
AstraZeneca’s drug Farxiga could receive a new indication for a subset of diabetes patients based on Phase III data that was released today.
Tecentriq’s Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.
Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space.
The FDA placed a hold on Advaxis’ Phase I/II trial following the death of a patient.
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
Merck and Tokyo-based Eisai Co. have signed a strategic collaboration deal to develop and commercialize Lenvima with Merck’s anti-PD-1 drug Keytruda.
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
JOBS
IN THE PRESS